Eniro Group - Cutting costs

Redeye updates its estimates and valuation following Eniro's Q2 2025 report and a change of lead analyst. The report was broadly below our estimates, where a 16% y/y sales decline in Dynava is seen as the main surprise. We lower our estimates somewhat across the forecasting period, and make a few valuation-related changes as a result of the analyst change. Our fair value range is lowered, although with slightly mixed effects across our three different scenarios.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/